JMP Securities Initiates Coverage On Sagimet Biosciences with Market Outperform Rating, Announces Price Target of $30
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jonathan Wolleben has initiated coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform rating and a price target of $30.
August 08, 2023 | 9:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sagimet Biosciences has been given a Market Outperform rating by JMP Securities with a price target of $30.
The initiation of coverage by JMP Securities with a Market Outperform rating and a price target of $30 indicates a positive outlook for Sagimet Biosciences. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100